Anthem Biosciences Board Approves New Auditor, INR 1,276.83M Promoter Payout

Anthem Biosciences Limited's Board of Directors has made two key decisions: appointing a new statutory auditor and approving a significant payout to promoters.

The company appointed S. R. Batliboi & Associates LLP as its new statutory auditors for a term of five years, concluding in FY 2031-2032. They will succeed K.P. Rao & Co., who will continue their duties until the conclusion of the 20th Annual General Meeting in FY 2026-2027.

The Board also approved an 'upside sharing arrangement'. This agreement is set to result in a payout of INR 1,276.83 million to the Upside Promoters. This payout stems from an investor's equity share divestment that occurred on March 09, 2026, where the investor sold 20,313,795 equity shares for INR 13,170 million.

This proposed payout to promoters is contingent upon approval from the company's public shareholders.

Significance of the Decisions

The appointment of S. R. Batliboi & Associates LLP, a prominent firm, signals an enhancement in Anthem Biosciences' governance and audit oversight, potentially bringing fresh perspectives and greater financial transparency. The approved payout helps to clarify a financial transaction linked to a past investor exit and allocates funds to promoters.

For investors, the immediate focus will be on the upcoming public shareholder vote on the upside sharing arrangement. The smooth transition of audit duties to the new firm will also be closely watched, alongside any future disclosures related to previously reported governance concerns.

Company Background

Anthem Biosciences, established in 2006, operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) within the pharmaceutical and biotechnology sectors. The company completed its initial public offering in July 2025. K.P. Rao & Co. served as its auditor for the financial year ending March 31, 2024.

Securities and Exchange Board of India (SEBI) regulations mandate public shareholder approval for new upside-sharing agreements, aiming to ensure equitable promoter compensation.

In the past, Anthem Biosciences disclosed a Code of Conduct violation by a designated person for trading during a restricted period, which contravened SEBI insider trading rules. A review of its RHP also previously highlighted governance concerns regarding cash flow disconnects and subsidiary loans.

Potential Risks

A primary risk for the company is the potential failure to secure the necessary approval from public shareholders for the proposed upside sharing arrangement, which could block the promoter payout. Additionally, investors will continue to monitor any ongoing implications from past governance issues, such as the Code of Conduct violations.

Peer Landscape

Anthem Biosciences operates in the CRDMO segment of India's pharmaceutical and biotechnology industry, alongside peers like Dr. Reddy's Laboratories, Biocon, and Sun Pharmaceuticals. While its peers often focus on R&D and drug manufacturing, Anthem's CRDMO model provides integrated services from drug discovery through to commercial production. This current news centers on governance and promoter remuneration rather than market share or R&D output.

Transaction Details

The investor's divestment on March 09, 2026, involved 20,313,795 equity shares and resulted in a net realization of INR 13,170 million for the seller.